Related Experiment Video
Updated: Aug 9, 2025
08:54
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
14.3K
Beta Blockers with Statins May Decrease All-Cause Mortality in Patients with Cardiovascular Diseases and Locally
Magdalena Zaborowska-Szmit1, Sebastian Szmit2,3, Marta Olszyna-Serementa1
1Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
Cancers
|February 25, 2023
Summary
Cardiovascular diseases (CVD) did not significantly impact survival in unresectable non-small-cell lung cancer (NSCLC) patients treated with chemoradiotherapy (CRT). However, beta-blockers and statins showed a trend towards reduced mortality in these patients.
Area of Science:
- Oncology
- Cardiology
- Clinical Pharmacology
Background:
- Maintenance immunotherapy with durvalumab was not standard after chemoradiotherapy (CRT) for unresectable non-small-cell lung cancer (NSCLC) during the study period.
- Cardiovascular diseases (CVD) are common comorbidities in patients undergoing cancer treatment.
- The impact of CVD and its pharmacotherapy on survival in NSCLC patients receiving CRT is not well-established.
Purpose of the Study:
- To investigate the effect of cardiovascular diseases (CVD) on overall survival (OS) in unresectable non-small-cell lung cancer (NSCLC) patients treated with sequential chemoradiotherapy (CRT).
- To assess whether pharmacotherapy for CVD influences OS in this patient population.
Main Methods:
- Retrospective analysis of 196 unresectable NSCLC patients undergoing sequential CRT.
- Patients were categorized based on the presence of CVD versus other reasons for CRT qualification.
- Overall survival (OS) and all-cause mortality were analyzed, with subgroup analysis for patients on beta-blockers and statins.
Main Results:
- 101 patients (51.53%) had CVD; these patients were older and had more cardiac/nephrological complications.
- A nonsignificant trend for lower all-cause mortality was observed in patients with CVD.
- Treatment with beta-blockers and statins was associated with significantly lower all-cause mortality and improved OS in patients with CVD undergoing CRT.
Conclusions:
- While CVD itself did not significantly worsen survival in NSCLC patients treated with CRT, specific pharmacotherapies showed promise.
- Beta-blockers and statins demonstrated a significant survival benefit in NSCLC patients with CVD undergoing radical CRT.
- Further prospective studies are warranted to confirm the role of beta-blockers and statins in reducing mortality in this context.
More Related Videos
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
411
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
411
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
918
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
918
01:28Antihypertensive Drugs: Types of β-Blockers
786
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
786
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
542
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
542
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
479
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
479
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
698
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
698